298 related articles for article (PubMed ID: 31117208)
1. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
Basnet S; Dhital R; Tharu B
Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
[TBL] [Abstract][Full Text] [Related]
2. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
[TBL] [Abstract][Full Text] [Related]
3. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
4. Interstitial nephritis with pembrolizumab: A case report and review.
Peláez Bejarano A; Montero Pérez O; Inoriza Rueda A; Garrido Martínez MT
J Oncol Pharm Pract; 2021 Jun; 27(4):1046-1051. PubMed ID: 33040674
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
[TBL] [Abstract][Full Text] [Related]
6. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
Shirali AC; Perazella MA; Gettinger S
Am J Kidney Dis; 2016 Aug; 68(2):287-291. PubMed ID: 27113507
[TBL] [Abstract][Full Text] [Related]
7. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
[TBL] [Abstract][Full Text] [Related]
8. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
9. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
10. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
Blanchard A; Bouchard N
Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
[TBL] [Abstract][Full Text] [Related]
12. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
14. IgA nephropathy after pembrolizumab therapy for mesothelioma.
Wang R; Das T; Takou A
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257374
[TBL] [Abstract][Full Text] [Related]
15. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
16. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer.
Fujita T; Hayama N; Kuroki T; Shiraishi Y; Amano H; Nakamura M; Hirano S; Aramaki N; Ichinose S; Shimizu S; Tabeta H; Nakamura S
Thorac Cancer; 2019 Nov; 10(11):2179-2182. PubMed ID: 31512401
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab-induced agranulocytosis.
Fernández Martínez V; García-Avello Fernández-Cueto A; Valencia Soto CM; Barbadillo Villanueva S; Ochagavía Sufrategui M; Rioja Carrera M; Alonso Buznego LA; Valero Domínguez M
J Oncol Pharm Pract; 2024 Jun; 30(4):767-771. PubMed ID: 38291678
[TBL] [Abstract][Full Text] [Related]
19. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]